Study Details

Back to Search Results

A study to compare the efficacy and safety of Tacrolimus capsules and Cyclophosphamide injection in treatment of lupus nephritis

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT02457221

Astellas Study ID

The unique identification code given by the study sponsor.

F506-CL-0912

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Follow Trial

Condition

Lupus

Phase

These clinical trials are done to confirm that an experimental treatment helps participants who have a specific condition. These clinical trials often compare the experimental treatment to another treatment or, if appropriate, a placebo.

Phase 3

Age

18 years - 60 years

Sex

Female & Male

Product

N/A

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Mar 2015 - Sep 2018

Masking

None (Open Label)

Enrollment number

314

A phase III, randomized, open, parallel-controlled, multi-center study to compare the efficacy and safety of Tacrolimus capsules and Cyclophosphamide injection in treatment of lupus nephritis

Study summary

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A study to compare the efficacy and safety of Tacrolimus capsules and Cyclophosphamide injection in treatment of lupus nephritis? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Site CN00020

Shijiazhuang, China

Site CN00041

Xiamen, China

Site CN00034

Beijing, China

Site CN00026

Changchun, China

Site CN00025

Nanjing, China

Site CN00047

Shijiazhuang, China

Site CN00017

Shenzhen, China

Site CN00014

Shanghai, China

Site CN00043

Hefei, China

Site CN00002

Chengdu, China

Site CN00027

Changsha, China

Site CN00030

Beijing, China

Site CN00001

Shanghai, China

Site CN00048

Lishui, China

Site CN00045

Liuzhou, China

Site CN00037

Nanning, China

Site CN00056

Guangzhou, China

Site CN00044

Wulumuqi, China

Site CN00010

Hangzhou, China

Site CN00019

Shenyang, China

Site CN00012

Nanjing, China

Site CN00018

Shenyang, China

Site CN00038

Nanning, China

Site CN00053

Tianjin, China

Site CN00023

Wuhan, China

Site CN00028

Zhengzhou, China

Site CN00013

Nanjing, China

Site CN00049

Wuxi, China

Site CN00052

Taiyuan, China

Site CN00032

Qingdao, China

Site CN00021

Tianjin, China

Site CN00024

Wuhan, China

Site CN00042

Changchun, China

Site CN00003

Chengdu, China

Site CN00015

Shanghai, China

Site CN00050

Changsha, China

Site CN00005

Dalian, China

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo